Clinical Trials Logo

Overweight and Obesity clinical trials

View clinical trials related to Overweight and Obesity.

Filter by:

NCT ID: NCT05055362 Completed - Clinical trials for Overweight and Obesity

Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study

Start date: September 22, 2021
Phase: N/A
Study type: Interventional

The purpose of this research is to determine the effect a spiced-infused baked good has on inflammatory biomarkers in adults who are overweight and/or who has chronic kidney disease. Participants will be involved for 10 days in this research study.

NCT ID: NCT05054530 Completed - Clinical trials for Overweight and Obesity

Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106

Start date: November 11, 2021
Phase: Phase 1
Study type: Interventional

This will be a single centre, Phase 1, placebo-control, randomized, double-blind, sequential single and multiple ascending dose study to assess the safety, tolerability, and PK of GMA106 in healthy, overweight or obese subjects.

NCT ID: NCT05054153 Completed - Healthy Clinical Trials

Westlake Precision Nutrition Study

Start date: October 8, 2021
Phase: N/A
Study type: Interventional

This is a dietary intervention study, which aims to explore different diet challenges for glucose metabolism, including carbohydrates and intermittent fasting (IF) dietary pattern. Considering the glucose responses to the same food are largely heterogeneous among people, this study integrates the concepts of precision nutrition and N-of-1 design. The study also aims to explore differences in brain structure and function between participants with different Body Mass Index (BMI) from the perspective of gut-brain axis.

NCT ID: NCT05051579 Completed - Obesity Clinical Trials

A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities

Start date: September 29, 2021
Phase: Phase 2
Study type: Interventional

The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight.

NCT ID: NCT05007964 Completed - Clinical trials for Overweight and Obesity

A Multi-Center Study to Evaluate the Adjustment Function of a Modified Spatz3 Adjustable Balloon (Spatz4)

Start date: June 14, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the function of the adjustment procedure with the Spatz4 in subjects with a BMI ≥ 27. Up to 66 eligible subjects will undergo endoscopy and those without endoscopic contraindications will be implanted with the Spatz4 balloon. All subjects will follow a calorie restricted diet designed by the dietician. An up adjustment will be performed at 16 weeks (±2 weeks). The subjects will be followed for 2 weeks after the up adjustment procedure, after which the study ends. Subjects will be given the option to continue the implantation period until 52 weeks.

NCT ID: NCT05004584 Completed - Clinical trials for Overweight and Obesity

Validation of Appetite Method Visual Analogue Scales in Home-setting: VASA-home

VASA-home
Start date: August 31, 2021
Phase: N/A
Study type: Interventional

The overall aim is to investigate whether there is a difference between methods when a standardized visual analogue scale is used to measure appetite in the home-setting compared to a monitored clinical setting. Furthermore, the intention is to investigate differences in appetite response between diets based on rye or wheat products, as well as the effects on postprandial metabolic response to such diets. Lastly, the effect of venous blood collection on subjective appetite response will be evaluated.

NCT ID: NCT04999280 Completed - Healthy Clinical Trials

Fiber-enriched Croissant Consumption and Effects on Metabolic Status, Appetite and Gut Microbiota

CROMA
Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the effect of a daily consumption for 2 weeks of a sourdough croissant enriched with dietary fibers vs a control sourdough croissant with no fiber added on daily energy intakes, fasting metabolic parameters, inflammatory status, blood pressure, anthropometric measures, body composition, appetite sensations, gastrointestinal functionality and gut microbiota composition.

NCT ID: NCT04994769 Completed - Clinical trials for Overweight and Obesity

The Effect of Extended Use of the EPITOMEE CAPSULE (ELECT)

Start date: August 31, 2021
Phase: N/A
Study type: Interventional

The Effect of Extended Use of the Epitomee Capsule on BodyWeight in subjects with Overweight and Obesity with and without Prediabetes

NCT ID: NCT04979234 Completed - Clinical trials for Overweight and Obesity

A Single Centre, Prospective Feasibility Study to Evaluate the Efficacy of an Endoluminal-suturing Device (Endomina) on Severe Obstructive Sleep Apnea Syndrome

EndoSAS
Start date: September 21, 2020
Phase: N/A
Study type: Interventional

This study aims to evaluate the efficacy of an endoluminal gastric plication using an endoluminal-suturing device to improve severe OSAS in patients with a BMI above or equal to 28 kg/m² until 34.9kg/m².

NCT ID: NCT04979065 Completed - Covid19 Clinical Trials

Nutrition, Immunity, and Covid-19 in Obese People

NICO
Start date: July 24, 2021
Phase: Phase 2
Study type: Interventional

The increased risk of transmission of COVID-19 infection causes the incidence of death in health workers to escalate. It requires further research on risk factors and intervention in health worker professionals, especially on immunity factors and nutritional status. Quality of diet and nutrition is very important to support the immune system when infected. Several probiotic strains have been shown to decrease the duration and incidence of diarrhea and respiratory infections, suggesting the Gut-Lung Axis pathway. Some probiotics also improve the balance of diversity in the composition of the gut microbiota and affect body weight in obese people. Probiotics have also been shown to improve vitamin D absorption. A combination of vitamin D and probiotics may be an alternative to reduce gut dysbiosis that will directly or indirectly reduce the risk and severity of viral infections including SARS-CoV-2.